Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Xencor Inc (XNCR)
A forensic read on Xencor Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
7.3
Distress distance
Clean
Earnings quality
3
Forensic signals
-11.4
P / E (ttm)
-14.5%
ROE
$1.8B
Market cap
0.00%
Dividend yield
13.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Xencor Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 7.3, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-18.2%
FY2025
Return on invested capital.Return on invested capital is -18.2% in the latest fiscal year and slipping across FY2023–FY2025 from -12.1%. After-tax operating profit was ($105M) in FY2023 and ($140M) in FY2025, with operating income at -75.8% of revenue in FY2023, -161.5% in FY2024 and -141.4% in FY2025. The capital base behind it came down -11% across FY2023–FY2025, from $865M to $769M, so this is a return struck on a smaller base rather than a record of money put to work.
+10.8%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +23% over the last 2 years to FY2025 (+10.8%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~10.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~19%.
34% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 34% of revenue in FY2025 — about $0.58 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 10.8% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$125.6M
Revenue Growth YoY+13.7%
Revenue CAGR (2yr)-15.2%
Net Margin-73.2%
Free Cash Flow-$138.3M
Return on Equity-14.5%
Debt / Equity0.19x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Xencor Inc's actual 10-K/10-Q/8-K filings?